Orthobiologics for Discogenic Back Pain: What the Evidence Shows

Chronic low back pain caused by a damaged or degenerating disc is one of the most frustrating conditions we treat. Many patients have already tried various treatments, including physical therapy, medications, and epidural steroid injections, before they ever hear the term orthobiologics. It's a rapidly growing area of musculoskeletal medicine, and one we're often asked about.

What Are Orthobiologics?

Orthobiologics are treatments that use substances naturally found in the body, such as blood or bone marrow, to support tissue healing. For disc-related back pain, three preparations come up most often:

• Platelet-Rich Plasma (PRP): a concentrated solution derived from the patient's own blood, rich in growth factors that support tissue repair.
• Bone Marrow Aspirate Concentrate (BMAC): a preparation drawn from the patient's bone marrow that contains mesenchymal stem cells and other regenerative components.
• Mesenchymal Stem Cells (MSCs): cells capable of developing into different tissue types, with potential to help repair damaged disc material.
  
  

The premise of these treatments is straightforward: deliver the body's own healing machinery directly into the disc to reduce pain and, ideally, support the disc's health.

What the Research Says About PRP

PRP is the most heavily studied orthobiologic for discogenic pain, and the data are encouraging, though not without caveats. A meta-analysis pooling six studies found meaningful reductions in pain at one, two, and six months post-injection, and roughly 50 to 65 percent of patients achieved at least a 30 percent reduction in pain at the six-month mark [Peng et al. 2023]. One long-term follow-up study suggested that benefits may persist for 5 to 9 years after a single injection. A 2026 prospective cohort of 45 patients found that nearly 80 percent reached meaningful improvement in both pain and function at six months, with MRI findings suggesting favorable changes within the disc itself [Sayed et al. 2022; Pan et al. 2026].

Not every trial has been this positive. Taken together, the evidence for PRP is promising but still developing, and current systematic reviews rate the overall quality of evidence as low.

Bone Marrow and Stem Cell Therapies

BMAC and MSC-based treatments have also shown positive signals. A review pooling 16 studies found a general improvement in pain compared with baseline, with some patients demonstrating greater disc height and hydration on MRI [Her et al. 2022]. However, in the highest-quality trials, these therapies did not consistently outperform placebo for pain or function once compared head-to-head [Navni et al. 2024].

Safety Profile

Orthobiologic injections are generally well tolerated, but any procedure that places a needle into a spinal disc carries a small, real risk of discitis or spondylodiscitis (infection of the disc space, sometimes involving the adjacent vertebral bone). Overall, infection after interventional spine procedures is uncommon, with large reviews citing rates of around 0.12 percent [Santiago et al. 2021].

Intradiscal procedures, specifically those where material is injected directly into the disc, appear to carry a higher risk, with small-sample data suggesting rates near 1 percent, and the risk climbing further when multiple disc levels are treated in the same session [Santiago et al. 2021].

Minimizing risk relies on strict sterile technique, careful patient selection, and limiting the number of levels treated per session. In addition, prophylactic antibiotic treatments and intradiscal antibiotic injections are considered.

What Patients Should Know Before Considering Treatment

A few points are worth keeping in mind before pursuing orthobiologic treatment for disc pain:

• The evidence is still evolving. Results are encouraging, but larger, higher-quality trials are needed before these treatments become standard of care.
• Preparation methods vary. How PRP or stem cells are processed differs from clinic to clinic, and this can meaningfully affect outcomes.
• Patient selection matters. Some disc problems respond better than others, which is why a thorough evaluation, often including advanced imaging, is an important first step.
• Be wary of overpromising. Any clinic guaranteeing results or marketing these treatments as a cure for degenerative disc disease should raise a red flag. The science is promising, but it is not a miracle cure, and honest providers will walk through both the potential benefits and the current limitations.
  
  

Our Approach at Desert Spine and Sports Physicians

At Desert Spine and Sports Physicians, our fellowship-trained physicians evaluate every patient with disc-related back pain individually, reviewing imaging and treatment history before recommending next steps. When orthobiologic treatment is appropriate, we discuss the current state of the evidence openly, including what it does and doesn't yet show, so that patients can make an informed decision as part of a broader, comprehensive pain management plan.

If you've been living with disc-related back pain and want to know whether orthobiologics might be a fit for you, we encourage you to schedule a consultation so we can review your imaging and treatment history together.

References

1. Peng B, Xu B, Wu W, et al. Efficacy of intradiscal injection of platelet-rich plasma in the treatment of discogenic low back pain: a single-arm meta-analysis. Medicine. 2023;102(10):e33112.
2. Schneider BJ, Hunt C, Conger A, et al. The effectiveness of intradiscal biologic treatments for discogenic low back pain: a systematic review. Spine J. 2022;22(2):226-237.
3. Sayed D, Grider J, Strand N, et al. The American Society of Pain and Neuroscience (ASPN) evidence-based clinical guideline of interventional treatments for low back pain. J Pain Res. 2022;15:3729-3832.
4. Zhang RE, Aurangzeb A, Sirisena D. Platelet-rich plasma and stem cell therapies for spondylosis: a systematic review of randomized controlled trials. Eur Spine J. 2026.
5. Pan X, Peng G, Yao Q, et al. Intradiscal platelet-rich plasma for discogenic low back pain: a prospective cohort study of early clinical outcomes and quantitative MRI findings. Sci Rep. 2026;16(1):14161.
6. Her YF, Kubrova E, Martinez Alvarez GA, D'Souza RS. The analgesic efficacy of intradiscal injection of bone marrow aspirate concentrate and culture-expanded bone marrow mesenchymal stromal cells in discogenic pain: a systematic review. J Pain Res. 2022;15:3299-3318.
7. Santiago K, Cheng J, Jivanelli B, Lutz G. Infections following interventional spine procedures: a systematic review. Pain Physician. 2021;24(2):101-116.